Affimed N.V. (0HL9.L)
USD 0.73
(1.12%)
USD 0.73
(1.12%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -106.66 Million EUR | -21.04% |
| 2022 | -88.11 Million EUR | -37.62% |
| 2021 | -64.03 Million EUR | -84.43% |
| 2020 | -34.71 Million EUR | -7.23% |
| 2019 | -32.37 Million EUR | -65.72% |
| 2018 | -19.53 Million EUR | 28.33% |
| 2017 | -27.26 Million EUR | 14.93% |
| 2016 | -32.04 Million EUR | -50.14% |
| 2015 | -21.34 Million EUR | -160.98% |
| 2014 | -8.17 Million EUR | 47.92% |
| 2013 | -15.7 Million EUR | -51.03% |
| 2012 | -10.39 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -19.53 Million EUR | 6.24% |
| 2024 Q2 | -15.55 Million EUR | 20.38% |
| 2023 Q1 | -31.46 Million EUR | -4.47% |
| 2023 FY | -106.66 Million EUR | -21.04% |
| 2023 Q2 | -29.44 Million EUR | 6.42% |
| 2023 Q4 | -20.83 Million EUR | 16.4% |
| 2023 Q3 | -24.92 Million EUR | 15.35% |
| 2022 FY | -88.11 Million EUR | -37.62% |
| 2022 Q3 | -19.2 Million EUR | 11.32% |
| 2022 Q2 | -21.66 Million EUR | -26.43% |
| 2022 Q1 | -17.13 Million EUR | 29.13% |
| 2022 Q4 | -30.11 Million EUR | -56.77% |
| 2021 FY | -64.03 Million EUR | -84.43% |
| 2021 Q1 | -4.08 Million EUR | 61.57% |
| 2021 Q2 | -17.2 Million EUR | -321.05% |
| 2021 Q3 | -18.56 Million EUR | -7.96% |
| 2021 Q4 | -24.17 Million EUR | -30.2% |
| 2020 Q4 | -10.62 Million EUR | -265.38% |
| 2020 FY | -34.71 Million EUR | -7.23% |
| 2020 Q3 | -2.9 Million EUR | 74.22% |
| 2020 Q2 | -11.28 Million EUR | -14.03% |
| 2020 Q1 | -9.89 Million EUR | 12.83% |
| 2019 Q3 | -12.35 Million EUR | -27.65% |
| 2019 Q2 | -9.68 Million EUR | -1051.08% |
| 2019 FY | -32.37 Million EUR | -65.72% |
| 2019 Q1 | 1.01 Million EUR | -89.42% |
| 2019 Q4 | -11.35 Million EUR | 8.14% |
| 2018 Q4 | 9.62 Million EUR | 179.31% |
| 2018 Q1 | -7.91 Million EUR | -34.97% |
| 2018 FY | -19.53 Million EUR | 28.33% |
| 2018 Q3 | -12.12 Million EUR | -33.08% |
| 2018 Q2 | -9.11 Million EUR | -15.18% |
| 2017 Q2 | -6.79 Million EUR | 6.84% |
| 2017 Q3 | -7.3 Million EUR | -7.37% |
| 2017 Q4 | -5.86 Million EUR | 19.68% |
| 2017 Q1 | -7.29 Million EUR | -13.41% |
| 2017 FY | -27.26 Million EUR | 14.93% |
| 2016 Q2 | -8.48 Million EUR | -18.87% |
| 2016 FY | -32.04 Million EUR | -50.14% |
| 2016 Q1 | -7.13 Million EUR | 2.35% |
| 2016 Q4 | -6.43 Million EUR | 35.55% |
| 2016 Q3 | -9.98 Million EUR | -17.65% |
| 2015 Q3 | -7.06 Million EUR | -42.2% |
| 2015 Q4 | -7.31 Million EUR | -3.51% |
| 2015 Q2 | -4.96 Million EUR | -148.1% |
| 2015 Q1 | -2 Million EUR | 64.47% |
| 2015 FY | -21.34 Million EUR | -160.98% |
| 2014 FY | -8.17 Million EUR | 47.92% |
| 2014 Q1 | -9.31 Million EUR | -591.46% |
| 2014 Q2 | 7.19 Million EUR | 177.28% |
| 2014 Q3 | -428 Thousand EUR | -105.95% |
| 2014 Q4 | -5.63 Million EUR | -1216.36% |
| 2013 Q1 | -2.56 Million EUR | 0.0% |
| 2013 Q4 | -1.34 Million EUR | 79.05% |
| 2013 Q2 | -5.36 Million EUR | -109.04% |
| 2013 FY | -15.7 Million EUR | -51.03% |
| 2013 Q3 | -6.42 Million EUR | -19.9% |
| 2012 FY | -10.39 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| uniQure N.V. | -282.87 Million USD | 62.293% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -121.288% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -9.557% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 107.901% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 72.755% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 62.2% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -45.129% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -91.3% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 61.356% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 53.991% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 154.855% |
| bluebird bio, Inc. | -244.26 Million USD | 56.333% |
| Blueprint Medicines Corporation | -486.27 Million USD | 78.066% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 12.21% |
| Imunon, Inc. | -21.03 Million USD | -407.175% |
| Adicet Bio, Inc. | -152.03 Million USD | 29.846% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 199.421% |
| Dynavax Technologies Corporation | -37.02 Million USD | -188.055% |
| Editas Medicine, Inc. | -169.18 Million USD | 36.955% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 85.316% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 31.435% |
| Exelixis, Inc. | 170.88 Million USD | 162.417% |
| FibroGen, Inc. | -281.81 Million USD | 62.152% |
| Geron Corporation | -193.94 Million USD | 45.004% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 131.596% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 3.575% |
| Illumina, Inc. | -1.06 Billion USD | 90.022% |
| Incyte Corporation | 620.52 Million USD | 117.189% |
| Insmed Incorporated | -709.62 Million USD | 84.969% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 79.301% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 69.847% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 76.841% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 105.395% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -172.421% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 109.81% |
| Evolus, Inc. | -49.23 Million USD | -116.645% |
| Myriad Genetics, Inc. | -123.7 Million USD | 13.774% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 142.511% |
| OPKO Health, Inc. | -157.02 Million USD | 32.072% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 60.175% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -1924.312% |
| Verastem, Inc. | -92.08 Million USD | -15.83% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.242% |
| Waters Corporation | 817.67 Million USD | 113.044% |
| Zoetis Inc. | 3.06 Billion USD | 103.475% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 102.476% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 101.555% |
| Biogen Inc. | 1.29 Billion USD | 108.225% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 61.073% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 102.635% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -136.618% |
| Homology Medicines, Inc. | -48.25 Million USD | -121.036% |
| Nektar Therapeutics | -137.42 Million USD | 22.386% |
| TG Therapeutics, Inc. | 20.63 Million USD | 616.944% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -5.786% |
| Perrigo Company plc | 151.9 Million USD | 170.218% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -138.792% |